Meet the 2018 Laureates: Shlomo Melmed, MD

Melmed, Shlomo 2015

2018 Outstanding Scholarly Physician Award

Shlomo Melmed, MD

Shlomo Melmed, MD, compellingly impacts the practice of pituitary medicine by clinical leadership, educational initiatives, and major translational discoveries in pathophysiology and therapy of pituitary disease.

He has elucidated mechanisms for paracrine pituitary growth factor regulation and pituitary tumorigenesis and identified novel molecules for pituitary tumor therapy. His landmark papers demonstrated mechanisms for pituitary tumorigenesis and intrapituitary ACTH and GH control. He described ectopic GH acromegaly syndrome, discovered pituitary tumor transforming gene, and pioneered receptor subtype-specific analogs for neuroendocrine tumor therapy. He showed that receptor subtype-specific somatostatin analogs target specific pituitary hormone production, discovered the utility of these subtype-specific analogs to enhance pituitary tumor therapy, leading to a new generation of pharmacologic agents, and was global PI for the U.S. registration trials for somatostatin analogs.

Few scholarly physicians have contributed more to our fundamental and clinical understanding of pituitary tumor biology as it is applied to the practice of endocrinology.

Developing rodent and zebrafish models of pituitary tumorigenesis faithfully recapitulating human disease, he identified targeted small molecule inhibitors for aggressive prolactinomas and Cushing disease. Both these discoveries have spawned investigator-initiated NIH-funded prospective clinical trials. He couples translational discoveries with leading roles in developing clinical guidelines, co-authoring three Endocrine Society pituitary medicine guidelines, leading pivotal investigator-initiated clinical trials, and creating original pituitary disease classification.

He is a global leader of clinical education for pituitary medicine as pituitary editor of both the major endocrinology textbooks used worldwide, Williams and Jameson and Degroot respectively, and pituitary co-author for Harrisons. As past editor-in-chief of Endocrinology, and currently of Pituitary, he exemplifies an international pituitary scholar and leader. His exemplary publications in the very highest-quality basic and clinical journals reflect a dual combination of outstanding basic and clinical creativity underscoring his standing as a leading international clinical scholar of pituitary medicine and discovery. Few scholarly physicians have contributed more to our fundamental and clinical understanding of pituitary tumor biology as it is applied to the practice of endocrinology.

You may also like

  • Endocrine Society Urges Congress to Increase Funding for NIH

    Funding needed by start of new fiscal year to advance public health during pandemic The Endocrine Society is calling on Congress to pass the House Labor-HHS spending bill to ensure health agencies are funded before the start of Fiscal Year 2021 and to avoid the tumult and disruption of a continuing resolution and potential government shutdowns. The…

  • Individuals Taking Class of Steroid Medications at High Risk for COVID-19

    JCEM Editors examine pandemic’s impact on endocrine patients in editorial Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according…